Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention

  Leukemia

  Free Subscription


15.08.2022

2 Acta Haematol
1 Ann Hematol
1 Biochem Biophys Res Commun
5 Blood
2 BMC Cancer
1 Bone Marrow Transplant
6 Br J Haematol
1 Cancer Chemother Pharmacol
2 Int J Hematol
3 Leuk Res
3 Leukemia
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. NACHMIAS B, Krichevsky S, Filon D, Even-Or E, et al
    Monitoring minimal residual disease in RUNX1-mutated acute myeloid leukemia.
    Acta Haematol. 2022 Aug 5. pii: 000526353. doi: 10.1159/000526353.
    PubMed         Abstract available

  2. HE X, Jiang Y, Yu X, He F, et al
    A gene signature comprising seven pyroptosis-related genes predicts prognosis in pediatric patients with acute myeloid leukemia.
    Acta Haematol. 2022 Aug 5. pii: 000526346. doi: 10.1159/000526346.
    PubMed         Abstract available


    Ann Hematol

  3. CHIRICHES C, Khan D, Wieske M, Guillen N, et al
    Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Ann Hematol. 2022 Aug 8. pii: 10.1007/s00277-022-04905.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  4. HAO C, Shao X, Song J, Peng M, et al
    Corrigendum to "SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia".
    Biochem Biophys Res Commun. 2022 Aug 8. pii: S0006-291X(22)01059.
    PubMed        


    Blood

  5. VOSO MT, Buccisano F
    AML: making residual disease more measurable.
    Blood. 2022;140:415-417.
    PubMed        

  6. SCARFO L, Herishanu Y
    CLL and COVID-19: light at the end of the tunnel?
    Blood. 2022;140:407-409.
    PubMed        

  7. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.
    Blood. 2022;140:516-520.
    PubMed        

  8. SHALABI H, Qin H, Su A, Yates B, et al
    CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Blood. 2022;140:451-463.
    PubMed         Abstract available

  9. NIEMANN CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, et al
    Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
    Blood. 2022;140:445-450.
    PubMed         Abstract available


    BMC Cancer

  10. CHEN B, Yang Z, Lang Z, Tao Q, et al
    M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    BMC Cancer. 2022;22:867.
    PubMed         Abstract available

  11. WEN J, Zhou M, Shen Y, Long Y, et al
    Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
    BMC Cancer. 2022;22:859.
    PubMed         Abstract available


    Bone Marrow Transplant

  12. ANDERSSON BS, Thall PF, Ma J, Valdez BC, et al
    A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan +/- clofarabine in allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 May 24. pii: 10.1038/s41409-022-01705.
    PubMed         Abstract available


    Br J Haematol

  13. LAURA CS, Ana FM, Ines LH
    Pure erythroid leukaemia mimicking metastatic carcinoma.
    Br J Haematol. 2022;198:617.
    PubMed        

  14. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed         Abstract available

  15. GENTHON A, Dragoi D, Memoli M, Hirsch P, et al
    Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:780-784.
    PubMed        

  16. MULLIGAN SP, Opat S, Marlton P, Kuss B, et al
    Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:790-793.
    PubMed        

  17. VOLPE VO, Al Ali N, Chan O, Padron E, et al
    Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Br J Haematol. 2022;198:713-720.
    PubMed         Abstract available

  18. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
    PubMed        


    Cancer Chemother Pharmacol

  19. ZHANG W, Liu J, Li Y, Guo F, et al
    A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.
    Cancer Chemother Pharmacol. 2022 Aug 12. pii: 10.1007/s00280-022-04462.
    PubMed         Abstract available


    Int J Hematol

  20. AYDIN S, Passera R, Scaldaferri M, Dellacasa CM, et al
    Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    Int J Hematol. 2022 Aug 9. pii: 10.1007/s12185-022-03427.
    PubMed         Abstract available

  21. TSUDA M, Hirata A, Tokunaga S, Masuda T, et al
    Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
    Int J Hematol. 2022 Aug 6. pii: 10.1007/s12185-022-03433.
    PubMed         Abstract available


    Leuk Res

  22. MARLEY AR, Ryder JR, Turcotte LM, Spector LG, et al
    Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms.
    Leuk Res. 2022;121:106924.
    PubMed         Abstract available

  23. KOLODRUBIEC J, Kozlowska M, Irga-Jaworska N, Sedek L, et al
    Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
    Leuk Res. 2022;121:106925.
    PubMed         Abstract available

  24. ORTI G, Garcia-Gutierrez V, Bautista G, Ferrer-Marin F, et al
    Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia.
    Leuk Res. 2022;121:106923.
    PubMed        


    Leukemia

  25. KONG W, He L, Zhu J, Bruck O, et al
    An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia.
    Leukemia. 2022 Aug 9. pii: 10.1038/s41375-022-01662.
    PubMed         Abstract available

  26. ZUNA J, Hovorkova L, Krotka J, Koehrmann A, et al
    Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
    Leukemia. 2022 Aug 6. pii: 10.1038/s41375-022-01668.
    PubMed         Abstract available

  27. MOSTOFI N, Shaw C, Walter RB, Percival MM, et al
    Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients.
    Leukemia. 2022 Aug 5. pii: 10.1038/s41375-022-01664.
    PubMed        


    PLoS One

  28. DONG K, Heidari M, Mays J, Chang S, et al
    A comprehensive analysis of avian lymphoid leukosis-like lymphoma transcriptomes including identification of LncRNAs and the expression profiles.
    PLoS One. 2022;17:e0272557.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: